The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

Abstract Background We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price negotiations after early benefit assessment between pharmaceutical companies and the German National Association of Statutory Health Insurance Funds. The analysis was conducted...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: C. M. Dintsios, I. Beinhauer
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMC 2020-03-01
Serie:Health Economics Review
Soggetti:
Study design
Negotiated prices
Oncological drugs
Pharmaceutical companies
Payers
German statutory health insurance
Accesso online:http://link.springer.com/article/10.1186/s13561-020-00263-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi